16 stories mentioning HTFLUpdated just now
Every FINWIRES story that references HTFL, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
John C.M. Farquhar, Director, Chief Executive Officer, on September 10, 2026, sold 38,900 shares in Heartflow (HTFL) for $1,819,605. Following the Form 4 filing with the SEC, Farquhar has control over a total of 321,914 common shares of the company, with 321,914 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000145/xslF345X05/form4.xml
Vikram Verghese, Chief Financial Officer, on September 08, 2026, sold 6,640 shares in Heartflow (HTFL) for $332,212. Following the Form 4 filing with the SEC, Verghese has control over a total of 214,503 common shares of the company, with 214,503 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000143/xslF345X05/form4.xml
Vikram Verghese, Chief Financial Officer, on September 02, 2026, sold 33,416 shares in Heartflow (HTFL) for $1,665,796. Following the Form 4 filing with the SEC, Verghese has control over a total of 221,143 common shares of the company, with 221,143 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000141/xslF345X05/form4.xml
John C.M. Farquhar, Director, Chief Executive Officer, on August 21, 2026, sold 27,230 shares in Heartflow (HTFL) for $1,361,500. Following the Form 4 filing with the SEC, Farquhar has control over a total of 360,814 common shares of the company, with 360,814 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000139/xslF345X05/form4.xml
John C.M. Farquhar, Director, Chief Executive Officer, on August 18, 2026, sold 32,676 shares in Heartflow (HTFL) for $1,470,420. Following the Form 4 filing with the SEC, Farquhar has control over a total of 388,044 common shares of the company, with 388,044 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000137/xslF345X05/form4.xml
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.6%.The iShares Biotechnology ETF (IBB) lost 0.6%.In corporate news, Luigi Mangione is expected to plead guilty to federal charges related to the killing of former UnitedHealth (UNH) executive Brian Thompson, according to his lawyer, multiple media outlets reported Friday. UnitedHealth shares were up 0.5%.Valneva (VALN) shares jumped 27% after the company and Pfizer (PFE) said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer shares were fractionally lower.Heartflow (HTFL) shares surged 33% after it posted a narrower Q2 non-GAAP loss, as revenue increased during the period, and raised its 2026 revenue outlook.
Healthcare stocks were flat to lower pre-bell Friday, with the iShares Biotechnology ETF (IBB) unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.2%.Heartflow (HTFL) stock was up nearly 24% after the company posted a narrower Q2 non-GAAP loss, as revenue increased during the period, and raised its 2026 revenue outlook.Valneva (VALN) shares were up nearly 26% after the company and Pfizer (PFE) said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer stock was 0.1% lower premarket.Capricor Therapeutics (CAPR) shares were up more than 85% after the company said the US Food and Drug Administration is willing to review an amendment to its biologics license application for deramiocel, potentially shifting the drug's focus to upper-limb skeletal muscle function in Duchenne muscular dystrophy.
Healthcare stocks were flat to lower pre-bell Friday, with the iShares Biotechnology ETF (IBB) unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.2%.Heartflow (HTFL) stock was up more than 24% after the company posted a narrower Q2 non-GAAP loss, as revenue increased during the period, and raised its 2026 revenue outlook.
(Updates with the stock move in the headline and the first paragraph.)Heartflow (HTFL) shares were up 24% in Friday's premarket activity after the company reported overnight a narrower-than-anticipated Q2 loss and a surge in revenue.The company reported late Thursday a Q2 non-GAAP loss of $0.07 per diluted share, compared with a loss of $2.79 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue for the quarter ended June 30 was $64.1 million, up from $43.4 million a year ago.Analysts expected $56.6 million.For 2026, Heartflow now expects revenue of $246 million to $250 million, up from the previously set out $228 million to $232 million. Analysts expect $230.1 million.Price: $38.44, Change: $+7.43, Percent Change: +23.96%
John C.M. Farquhar, Director, Chief Executive Officer, on August 10, 2026, sold 22,562 shares in Heartflow (HTFL) for $638,730. Following the Form 4 filing with the SEC, Farquhar has control over a total of 436,280 common shares of the company, with 436,280 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000127/xslF345X05/form4.xml
HeartFlow, Inc. (HTFL) has an average rating of buy and mean price target of $36.62, according to analysts polled by FactSet.
John C.M. Farquhar, Director, Chief Executive Officer, on June 24, 2026, sold 38,900 shares in Heartflow (HTFL) for $1,361,500. Following the Form 4 filing with the SEC, Farquhar has control over a total of 457,935 common shares of the company, with 457,935 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000097/xslF345X05/form4.xml
John C.M. Farquhar, Director, Chief Executive Officer, on May 11, 2026, sold 22,562 shares in Heartflow (HTFL) for $657,005. Following the Form 4 filing with the SEC, Farquhar has control over a total of 519,397 common shares of the company, with 519,397 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000067/xslF345X05/form4.xml
Heartflow, Inc. (HTFL) has an average rating of Buy and mean price target of $37.67, according to analysts polled by FactSet.
John C.M. Farquhar, Director, Chief Executive Officer, on April 10, 2026, sold 22,562 shares in Heartflow (HTFL) for $602,857. Following the Form 4 filing with the SEC, Farquhar has control over a total of 549,163 common shares of the company, with 549,163 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000055/xslF345X05/form4.xml
Heartflow (HTFL) said Monday it has lodged a patent infringement complaint against Cleerly in a Texas district court regarding the unapproved application of its coronary artery disease technology.Heartflow alleges that Cleerly's Ischemia, Plaque Analysis, and Compare products infringe six of its patents, according to a statement.Cleerly did not immediately respond to' request for a comment.Price: $26.31, Change: $-0.64, Percent Change: -2.37%
